FIG 3.

PARP inhibition alters CTCF binding across the Epstein-Barr virus genome. (A) ChIP-seq for CTCF across the EBV genome in untreated or olaparib-treated (PARPi) LCLs and respective input DNA. Peaks are expressed as counts per million reads. Corresponding genes in the linearized EBV genome are shown below. (B) Zoomed image of CTCF ChIP-seq at the latent Cp locus in LCLs, demonstrating the loss of enrichment after olaparib treatment. (C) Independent ChIP-qPCR validation of CTCF enrichment at Cp in untreated or olaparib-treated LCLs. qPCR data are presented as fold above the level for IgG. Results are representative of three independent experiments and show means ± standard deviations. (D) ChIP-qPCR for PARP1 in untreated or olaparib-treated LCLs. qPCR data are presented as fold above the level for IgG. Results are representative of three independent experiments and show means ± standard deviations (ns, not significant).